Summary
BeiGene, Ltd. (ONC) announced clinical data from two pivotal trials of its anti-PD-1 antibody tislelizumab at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The presented data includes results from the Phase 3 RATIONALE 302 trial for advanced/metastatic esophageal squamous carcinoma and a Phase 2 trial in patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) solid tumors. These updates are significant as they showcase progress in tislelizumab's development for various cancer types, a key asset for the company. Additionally, BeiGene presented data on its PARP inhibitor, pamiparib, from two Phase 2 trials. Efficacy was observed in HER2-negative breast cancer patients, while the gastric cancer trial showed numerically higher but not statistically significant progression-free survival, potentially due to lower-than-planned enrollment. These presentations at ASCO 2021 provide investors with crucial updates on the company's pipeline advancements and the clinical performance of its drug candidates.
Key Highlights
- 1BeiGene presented pivotal clinical data for its anti-PD-1 antibody, tislelizumab, at ASCO 2021.
- 2Data included Phase 3 RATIONALE 302 trial results for tislelizumab in advanced esophageal squamous carcinoma.
- 3Tislelizumab data was also presented for MSI-high or dMMR solid tumors.
- 4The company also showcased data from two Phase 2 trials of its PARP inhibitor, pamiparib.
- 5Pamiparib demonstrated efficacy in HER2-negative breast cancer patients.
- 6Gastric cancer trial results for pamiparib showed numerically higher but not statistically significant progression-free survival.
- 7The reduced statistical significance in the gastric cancer pamiparib trial may be attributed to under-enrollment.